GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Biodesix Inc.
Biodesix is a company specializing in diagnostic tests for lung cancer. Its stock price reflects the adoption of its tests in clinical practice. The chart is a growth story in the field of personalized medicine, where diagnostics play a key role.
Share prices of companies in the market segment - Cancer analysis
Biodesix is a diagnostics company that provides blood-based tests to support decision-making in lung cancer treatment. We've categorized it as "Cancer Analysis." The chart below shows how the market values companies developing personalized medicine.
Broad Market Index - GURU.Markets
Biodesix is a diagnostics company that provides blood-based tests to support decision-making in lung cancer treatment. It is a component of the GURU.Markets index. The chart below represents the market. See how its stock compares to the diagnostics sector.
Change in the price of a company, segment, and market as a whole per day
BDSX - Daily change in the company's share price Biodesix Inc.
For Biodesix, Inc., a lung diagnostics company, daily volatility reflects sensitivity to news about the rollout of its tests. This metric is an indicator of demand for personalized medicine in oncology.
Daily change in the price of a set of shares in a market segment - Cancer analysis
Biodesix, Inc. is a diagnostics company. This chart highlights the high volatility of the healthcare sector. Comparison with BDSX, which focuses on lung testing, helps us assess it as an innovative player.
Daily change in the price of a broad market stock, index - GURU.Markets
Biodesix is a company specializing in lung cancer diagnostics using blood and data analysis. Its shares are reacting to news of its tests being accepted by the medical community. This specific volatility, driven by medical innovation, feeds into the overall market movement.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Biodesix Inc.
For Biodesix, Inc., year-over-year performance tells the story of its role in lung cancer diagnostics. Its 12-month market cap growth reflects the growing number of doctors using its blood-based and proteomic tests to select treatments and monitor the disease, making it a key player in personalized oncology.
Annual dynamics of market capitalization of the market segment - Cancer analysis
Biodesix, Inc. is a company specializing in diagnosing lung diseases using blood and data analysis. Its innovative tests aid in cancer treatment. The chart below shows how its scientific advancements and commercialization efforts are impacting its performance in the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biodesix, specializing in lung cancer diagnostics, operates in the defensive healthcare sector. Demand for cancer tests is unaffected by economic cycles. The company's share price performance reflects the long-term trend toward personalized medicine and early detection.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Biodesix Inc.
Biodesix is a company specializing in lung disease diagnostics. Its monthly growth reflects the growth of testing volumes and the adoption of its tests in clinical practice. Quarterly revenue reports and partnerships with pharmaceutical companies are key drivers.
Monthly dynamics of market capitalization of the market segment - Cancer analysis
Biodesix is a company specializing in lung cancer diagnostics. It uses blood tests and artificial intelligence to assist doctors in making treatment decisions. The chart below reflects the general sentiment in the cancer diagnostics sector, where early and accurate testing saves lives.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biodesix, Inc. is a company specializing in lung cancer diagnostics. Its success depends on the adoption of its tests in clinical practice. Share price performance is driven by test volume growth reports, insurer coverage decisions, and scientific data, rather than by overall market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Biodesix Inc.
Shares of Biodesix, a lung cancer diagnostic company, fluctuate weekly based on oncology news. Data on the acceptance of its tests by doctors, changes in insurance coverage, and partnerships with pharmaceutical companies create high volatility.
Weekly dynamics of market capitalization of the market segment - Cancer analysis
Biodesix and the entire sector of companies developing "liquid biopsy" are moving against a backdrop of scientific breakthroughs and expectations. Regulatory news and clinical trial data are creating high volatility for everyone. The chart below shows how the company stacks up against this innovative backdrop.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Biodesix and the entire sector of companies developing "liquid biopsy" are moving against a backdrop of scientific breakthroughs and expectations. Regulatory news and clinical trial data are creating high volatility for everyone. The chart below shows how the company stacks up against this innovative backdrop.
Market capitalization of the company, segment and market as a whole
BDSX - Market capitalization of the company Biodesix Inc.
Biodesix's market capitalization is the financial valuation of a company providing diagnostic tests based on blood analysis and genomics to aid in the treatment of lung cancer. The chart reflects the demand for its services in personalized oncology. Its dynamics tell the story of how investors assess its path to profitability and widespread adoption of its tests.
BDSX - Share of the company's market capitalization Biodesix Inc. within the market segment - Cancer analysis
Biodesix is a company specializing in lung disease diagnostics, providing proteomics and genomics-based tests to aid in the treatment of lung cancer. Its market share reflects its leadership in this niche. The chart below shows this innovator's position in personalized oncology.
Market capitalization of the market segment - Cancer analysis
Biodesix is a diagnostics company specializing in lung diseases. The chart below shows the overall market capitalization of the entire sector. Its dynamics reflect the search for more accurate and personalized diagnostics and treatment methods. Biodesix operates at the intersection of genomics, proteomics, and artificial intelligence.
Market capitalization of all companies included in a broad market index - GURU.Markets
Cancer diagnostics, as shown in the graph, are becoming increasingly personalized. Biodesix offers a suite of blood- and tissue-based tests that help doctors choose treatments for lung cancer patients. Its success stems from its multi-platform approach to diagnostics.
Book value capitalization of the company, segment and market as a whole
BDSX - Book value capitalization of the company Biodesix Inc.
Biodesix's book value is the foundation for precision medicine in oncology. The chart reflects the value of its laboratories, equipped to perform proteomic and genomic tests, which help doctors tailor treatments for lung cancer patients.
BDSX - Share of the company's book capitalization Biodesix Inc. within the market segment - Cancer analysis
Biodesix, a diagnostics company, has cutting-edge laboratories. Its share of the sector's assets is its capacity to conduct proteomic and genomic testing for lung cancer patients. This physical infrastructure forms the foundation for providing personalized medical information.
Market segment balance sheet capitalization - Cancer analysis
Biodesix, Inc. is a diagnostics company, making its model moderately capital-intensive. It doesn't require large manufacturing facilities, but it does require certified labs with expensive equipment to conduct its tests. Compared to the healthcare sector, its model is based on technological infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Biodesix's assets are not drugs, but a suite of diagnostic tests based on blood analysis and genomics that help doctors make decisions about lung cancer treatment. The company's balance sheet reflects the value of this "smart" laboratory. The chart shows the capital invested in personalized oncology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Biodesix Inc.
Biodesix is a company specializing in lung disease diagnostics. Its market value is determined by its portfolio of tests and its ability to help doctors make more informed decisions. Investors are paying for its science and its role in personalized medicine.
Market to book capitalization ratio in a market segment - Cancer analysis
Biodesix is a company that provides diagnostic tests that aid in the treatment of lung cancer. Its value lies in its scientific data and tests. This chart shows how the market views its ability to integrate its tests into standard clinical practice.
Market to book capitalization ratio for the market as a whole
Biodesix develops diagnostic tests for decision-making in oncology. The company's value lies in its unique technologies and patents, not in its lab equipment. The chart clearly demonstrates the enormous premium the market is paying for the potential of this technology to personalize cancer treatment and improve outcomes.
Debts of the company, segment and market as a whole
BDSX - Company debts Biodesix Inc.
Biodesix provides diagnostic solutions for oncology, helping to personalize treatment. The company's growth depends on investment in research to validate and develop new tests, as well as in marketing to promote them among physicians. Debt financing can accelerate these processes and expand the availability of tests.
Market segment debts - Cancer analysis
Biodesix, Inc. provides diagnostic solutions for oncology. Investments in R&D and commercialization are crucial in the medical diagnostics sector. This chart shows how the company funds the development and promotion of its tests, which help doctors make decisions about lung cancer treatment, and how it manages its balance sheet to achieve profitability.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Biodesix Inc.
Biodesix, a company specializing in lung cancer diagnostics, incurs significant expenses on research and commercialization of its tests. This chart shows its reliance on debt. In the medical diagnostics industry, high debt is a bet on the tests being accepted by doctors and covered by insurance. Any delay along the way is dangerous.
Market segment debt to market segment book capitalization - Cancer analysis
Biodesix is a diagnostics company that provides doctors with blood-based data to guide treatment decisions for lung cancer. This chart compares the debt it raised for commercialization and test development to the total market capitalization of the entire cancer testing sector. It illustrates the financial implications of personalized medicine.
Debt to book value of all companies in the market
Biodesix provides diagnostic tests for oncology, helping to personalize treatment. Growth in this field requires investment in research, lab equipment, and marketing. The chart shows how the company is funding its expansion. Its debt load, compared to the biotech and diagnostics sector, reflects its market capture strategy.
P/E of the company, segment and market as a whole
P/E - Biodesix Inc.
For Biodesix, a cancer diagnostics company, this chart evaluates its testing portfolio. The price-to-earnings ratio shows whether investors believe its diagnostic products will become the standard in oncology. The price-to-earnings ratio reflects sales growth and insurance reimbursement.
P/E of the market segment - Cancer analysis
This chart shows the average valuation for the biotech diagnostics sector—a benchmark for Biodesix. Comparison with this metric helps investors understand how the market views the company's testing portfolio and its ability to grow sales in the competitive cancer diagnostics market.
P/E of the market as a whole
Biodesix is a company specializing in lung disease diagnostics. It provides tests that help doctors make treatment decisions for lung cancer and other conditions. This chart reflects sentiment in the healthcare sector. It helps understand how the introduction of personalized medicine is impacting demand for Biodesix's diagnostic tests and how the market views its scientific developments.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Biodesix Inc.
Biodesix provides diagnostic tests for oncology decision-making, primarily for lung cancer. The company's future profitability depends on how widely its tests are used by doctors. This chart shows whether analysts believe Biodesix's diagnostic solutions will become standard and covered by insurance.
%20P%2FE%20Biodesix%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Biodesix-Inc.&v=1772636213711 "Chart of the company's future (projected) P/E Biodesix Inc.")
Future (projected) P/E of the market segment - Cancer analysis
Biodesix is a diagnostics company that provides blood and tissue testing to support treatment decisions for lung cancer. This chart compares its future profitability expectations with those of the medical technology sector. It demonstrates how the market views its multidisciplinary approach to diagnostics and its ability to integrate its tests into clinical practice.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-analysis&v=1772636213718 "Future (projected) P/E graph of the market segment - Cancer analysis")
Future (projected) P/E of the market as a whole
Biodesix is a company specializing in diagnostics for lung diseases, including cancer. This chart shows the overall sentiment in the healthcare sector. For BDSX, the key factors aren't the economics, but rather the acceptance of their tests by oncologists and reimbursement from insurance companies. This is a growth story driven by improved diagnostics.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772636213765 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Biodesix Inc.
Biodesix is a company specializing in lung disease diagnostics. It provides doctors with a range of blood and tissue-based tests that help inform lung cancer treatment decisions. This chart shows financial results based on the number of tests performed and insurance reimbursement.
Profit of companies in the market segment - Cancer analysis
Biodesix is a company specializing in lung disease diagnostics. It provides physicians with a range of genomics and proteomics-based tests to inform lung cancer treatment decisions. This chart shows the financial pulse of the oncology diagnostics sector, reflecting the growing demand for personalized approaches that help select the right treatment.
Overall market profit
Biodesix is a company specializing in lung cancer diagnostics. Demand for their tests is driven by medical needs and is not affected by economic cycles. This provides stability for the business. However, the speed of adoption of new diagnostic methods and their coverage by insurance companies can be impacted by the overall state of the healthcare system.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Biodesix Inc.
Biodesix is a company specializing in diagnostics for lung diseases, including cancer. It provides doctors with blood and tissue-based tests to assist in treatment decisions. This graph reflects analysts' expectations for increased testing volumes and the adoption of its diagnostic products.
%20profit%20of%20the%20company%20Biodesix%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Biodesix-Inc.&v=1772636213964 "Graph of future (projected) profit of the company Biodesix Inc.")
Future (predicted) profit of companies in the market segment - Cancer analysis
Biodesix is a company specializing in diagnosing lung diseases, including cancer, using genomic and proteomic tests. This chart shows forecasts for the molecular diagnostics sector. Biodesix's profitability depends on the implementation of its tests in clinical practice to help doctors make treatment decisions and monitor patients with lung diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-analysis&v=1772636213968 "Graph of future (predicted) profits of companies in a market segment - Cancer analysis")
Future (predicted) profit of the market as a whole
Biodesix provides diagnostic tests for cancer patients, helping to personalize treatment. Demand for these cutting-edge services depends on their inclusion in insurance coverage and healthcare system budgets. This graph, which displays profit forecasts, is an indicator of the overall economic health, which impacts healthcare funding and innovation.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772636213972 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Biodesix Inc.
Biodesix is a company specializing in diagnostic tests for lung cancer that help doctors make treatment decisions. This chart shows how investors view its revenue. It reflects its belief in the growth of personalized medicine and the importance of its tests in improving patient outcomes.
P/S market segment - Cancer analysis
Biodesix is a company specializing in lung disease diagnostics. It provides blood- and tissue-based tests that help doctors make decisions about lung cancer treatment. This chart reflects the average valuation in the diagnostics sector, helping to understand how the market values Biodesix's portfolio of tests and their role in personalized oncology medicine.
P/S of the market as a whole
Biodesix provides blood-based diagnostic tests that help doctors make decisions about lung cancer treatment. This is the field of personalized medicine. This chart shows the premium investors are willing to pay for the revenue of a company whose technologies help make cancer treatment more precise and effective.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Biodesix Inc.
Biodesix is a company specializing in diagnosing lung diseases, including cancer. It offers a range of tests that help doctors make treatment decisions. This chart reflects investors' confidence in the future commercial success of its diagnostic products. The valuation is based on expected revenue from sales of these tests.
%20P%2FS%20Biodesix%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Biodesix-Inc.&v=1772636214043 "The graph of the company's future (projected) P/S Biodesix Inc.")
Future (projected) P/S of the market segment - Cancer analysis
Biodesix provides diagnostic tests that help doctors make decisions about lung cancer treatment. This chart compares the company's future revenue expectations with its sector. It reflects investors' belief that personalized medicine will become standard and that Biodesix's tests will be widely used.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-analysis&v=1772636214044 "Future (projected) P/S market segment graph - Cancer analysis")
Future (projected) P/S of the market as a whole
Biodesix is a company specializing in diagnosing lung diseases, including cancer, using blood-based tests and artificial intelligence. The optimism expressed by this indicator is fueled by innovation in medicine. Biodesix's technologies help doctors make more informed decisions, which is part of the trend toward personalized medicine.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772636214045 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Biodesix Inc.
Biodesix is a company specializing in lung cancer diagnostics. Revenue, shown in this chart, is generated from blood and tissue-based testing services that help doctors make treatment decisions for patients. Growth reflects the increasing number of tests performed and their expanded use.
Sales of companies in the market segment - Cancer analysis
Biodesix is a company specializing in diagnosing lung diseases, including cancer. They use a range of technologies, from proteomics to genomics, to help doctors make treatment decisions. This graph illustrates the growing personalized medicine market, where accurate diagnostics like Biodesix's are key to successful treatment.
Overall market sales
Biodesix, Inc. provides diagnostic tests for oncology decision-making. The implementation of its tests depends on healthcare system budgets. The increase in overall economic revenue, reflected in this graph, improves funding for clinics and insurance companies, allowing them to more actively utilize advanced diagnostic tools to personalize cancer treatment.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Biodesix Inc.
Biodesix, Inc. is a company specializing in lung disease diagnostics. It provides physicians with a range of blood- and tissue-based tests that help guide lung cancer treatment decisions. This chart shows analysts' expectations for the adoption of its diagnostic products in oncology practice.
%20sales%20of%20the%20company%20Biodesix%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Biodesix-Inc.&v=1772636214135 "Schedule of future (projected) sales of the company Biodesix Inc.")
Future (projected) sales of companies in the market segment - Cancer analysis
Biodesix is a company specializing in lung disease diagnostics. It provides proteomics and genomics-based tests that help doctors make lung cancer treatment decisions. This chart shows forecasts for the oncology diagnostics sector, illustrating the move toward personalized medicine and precise diagnostics.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-analysis&v=1772636214136 "Schedule of future (projected) sales of companies in the market segment - Cancer analysis")
Future (projected) sales of the market as a whole
Biodesix, a company specializing in lung cancer diagnostics, sees this chart as an indicator of the implementation of personalized medicine. The economic growth reflected here allows the healthcare system to invest more in advanced diagnostic tests that help doctors select the most effective treatment for each patient.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772636214146 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Biodesix Inc.
Biodesix is a company providing diagnostic services in pulmonology. It offers tests that help doctors make treatment decisions for lung diseases. Profitability depends on the number of tests performed and the level of reimbursement from insurance companies. This chart shows how successfully the company monetizes its diagnostic technologies.
Market segment marginality - Cancer analysis
Biodesix is a company specializing in lung disease diagnostics, including cancer. They use genomic and proteomic tests to assist physicians in decision-making. Profitability in this field depends on the accuracy of the tests and their implementation in clinical practice. The graph demonstrates the effectiveness of their science-based model.
Market marginality as a whole
Biodesix is a company specializing in lung disease diagnostics, including cancer. Despite its overall profitability, Biodesix operates in the field of personalized medicine. Their profitability depends on the adoption of their tests by oncologists to guide treatment decisions for patients.
Employees in the company, segment and market as a whole
Number of employees in the company Biodesix Inc.
Biodesix is a data-driven diagnostics company focused on lung diseases. This chart shows its team of scientists and technicians. The growth reflects the increase in the number of tests performed and efforts to develop and commercialize new diagnostic products.
Share of the company's employees Biodesix Inc. within the market segment - Cancer analysis
Biodesix is a company specializing in diagnostics for lung diseases, including cancer. Its tests help doctors make more accurate treatment decisions. This chart shows the percentage of all scientists and technicians in the oncology diagnostics sector that Biodesix employs, a measure of its scientific potential and the uniqueness of its multiomics platform.
Number of employees in the market segment - Cancer analysis
Biodesix is a company specializing in lung cancer diagnostics using AI-powered blood and tissue tests. Its staff consists of scientists, technicians, and sales personnel. This chart shows how the company is commercializing its tests. The growth in staff, particularly in sales, reflects its efforts to implement them into clinical practice.
Number of employees in the market as a whole
Biodesix provides diagnostic tests in the field of oncology. The personalized medicine sector is growing rapidly. This chart shows the overall economic situation, but for Biodesix, the driving force is scientific progress and the introduction of new, more accurate cancer diagnostic methods into clinical practice.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Biodesix Inc. (BDSX)
Biodesix is a diagnostics company. Its value lies in its unique tests and technologies. This metric reflects how much the market values these intangible assets. A high value on the chart indicates the great potential of its diagnostic platform.
%20of%20the%20company%20Biodesix%20Inc.%20(BDSX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Biodesix-Inc.-BDSX&v=1772636214366 "Chart of market capitalization per employee (in thousands of dollars) of the company Biodesix Inc. (BDSX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer analysis
Biodesix, Inc. provides blood testing solutions that aid in cancer treatment. In the field of medical diagnostics, a company's value is determined by the accuracy of its tests and their acceptance by the medical community. This metric reflects how the market perceives its technology and commercial potential per employee.
%20by%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-analysis&v=1772636214371 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer analysis")
Market capitalization per employee (in thousands of dollars) for the overall market
Biodesix is a company specializing in diagnostics for lung diseases, including cancer. It uses proteomics and genomics to personalize treatment. This chart shows how the market values this research-intensive diagnostics company, whose tests help doctors make more informed decisions, creating high value per employee.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772636214388 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Biodesix Inc. (BDSX)
Biodesix is a diagnostics company that provides blood- and AI-based tests to aid in the treatment of lung cancer. This chart shows how successfully the company is commercializing its tests. It reflects how much revenue each employee (laboratory, sales) generates from performing these complex diagnostic tests.
%20Chart%20Biodesix%20Inc.%20(BDSX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Biodesix-Inc.-BDSX&v=1772636214407 "Company Profit Per Employee (in thousands of dollars) Chart Biodesix Inc. (BDSX)")
Profit per employee (in thousands of dollars) in the market segment - Cancer analysis
Biodesix (BDSX) is a diagnostics company providing proteomics and genomics-based tests to aid in the treatment of lung cancer. For a diagnostics company, this metric reflects commercial efficiency. It shows how much revenue the laboratory and sales department generate per employee by processing tests and promoting them to oncologists.
%20in%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-analysis&v=1772636214420 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer analysis")
Profit per employee (in thousands of dollars) for the market as a whole
Biodesix is a company specializing in lung cancer diagnostics using blood tests (liquid biopsy) and AI. It's a high-tech medical service. This chart shows how successfully the company is monetizing its tests. Revenue per employee (lab technician, data analyst) will increase as more oncologists use their tests.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772636214446 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Biodesix Inc. (BDSX)
Biodesix is a company specializing in diagnosing lung diseases, including cancer. This chart shows how their research is being converted into commercial services. Growing revenue per employee indicates that more and more doctors are using their diagnostic tests, and the company is effectively scaling its laboratory operations.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Biodesix-Inc.-BDSX&v=1772636214464 "Sales chart per company employee Biodesix Inc. (BDSX)")
Sales per employee in the market segment - Cancer analysis
Biodesix is a diagnostics company that provides blood-based and genomic tests to aid in the treatment of lung cancer. This is a "liquid biopsy." This chart shows the average revenue per employee in the sector. It helps assess how productive the Biodesix team and their lab are in providing these advanced diagnostic services to oncologists.
Sales per employee for the market as a whole
Biodesix, Inc. (BDSX) is a lung cancer diagnostics company. They provide physicians with a suite of tests (proteomics and genomics) that help guide treatment decisions. This chart shows how successfully their lab and sales team are commercializing these sophisticated diagnostic tests, generating revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Biodesix Inc. (BDSX)
Biodesix is a company specializing in lung cancer diagnostics, using AI and blood tests to assist doctors in decision-making. It's a complex market. The chart shows the number of investors betting that the company's tests won't be widely adopted by oncologists or that insurance companies will refuse to reimburse them, limiting commercial success.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Biodesix-Inc.-BDSX&v=1772636214526 "Short Shares Chart for the Company Biodesix Inc. (BDSX)")
Shares shorted by market segment - Cancer analysis
Biodesix is a company specializing in lung cancer diagnostics, using proteomics and genomics to personalize treatment. This chart reflects the overall pessimism in the sector. If it rises, investors doubt that new diagnostic tests will be widely adopted or reimbursed by insurers.
Shares shorted by the overall market
Biodesix develops diagnostic tests (including liquid biopsy) for oncology. This is cutting-edge medicine, but not yet widely profitable. This chart reflects the general fear. When investors are pessimistic, they doubt the speed of adoption of new tests and the reimbursement system (insurance). This puts pressure on BDSX shares, which need revenue growth to cover R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Biodesix Inc. (BDSX)
Biodesix, Inc. provides blood-based diagnostic tests for lung cancer patients. This helps doctors choose the right treatment. This indicator measures the market's reaction to news about the introduction of their tests or insurance company decisions, showing "overheated" (above 70) on good news or "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Biodesix-Inc.-BDSX&v=1772636214720 "RSI 14 indicator chart for the company's stock Biodesix Inc. (BDSX)")
RSI 14 Market Segment - Cancer analysis
Biodesix (BDSX) is a "liquid biopsy" for *lungs*. Their *tests* (blood, AI) help *diagnose* lung cancer and *select* therapy (based on *proteomics*). The "Cancer Analysis" sector (biotech/diagnostics) thrives on R&D. RSI\_14\_Seg shows the "temperature" of the *entire* industry. It helps understand: is BDSX's growth their "niche" or the *general* "hype"?
RSI 14 for the overall market
Biodesix (BDSX), a cancer diagnostics company, is critically dependent on sentiment, as this chart shows. Market euphoria means open capital markets, making it easy to fund expensive clinical trials. In moments of market panic, investors flee unprofitable biotechs.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BDSX (Biodesix Inc.)
Biodesix is a liquid biopsy company. They provide blood-based diagnostic tests for lung cancer patients, helping doctors choose treatment. This chart shows the analysts' average 12-month forecast, reflecting their view on how quickly these tests will be implemented into clinical practice.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BDSX-Biodesix-Inc.&v=1772636214961 "A chart showing analyst consensus forecasts for the expected stock price. BDSX (Biodesix Inc.)")
The difference between the consensus estimate and the actual stock price BDSX (Biodesix Inc.)
Biodesix is a diagnostics company. It uses AI and proteomics to create tests (Nodify) that help doctors make decisions about lung cancer treatment. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and the forecast, reflecting their confidence in the implementation of these "smart" tests.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BDSX-Biodesix-Inc.&v=1772636214977 "A chart showing the difference between the consensus forecast and the actual stock price. BDSX (Biodesix Inc.)")
Analyst consensus forecast for stock prices by market segment - Cancer analysis
Biodesix is a diagnostic company that uses AI and liquid biopsy (blood tests) to aid in lung cancer treatment. It's at the cutting edge of diagnostics. This chart shows analysts' overall expectations for the entire cancer testing sector. It reflects whether experts believe complex diagnostic tests will be commercially successful.
Analysts' consensus forecast for the overall market share price
Biodesix is a company specializing in lung cancer diagnostics. They offer liquid biopsies (blood tests) and other tests that help doctors choose treatment. This chart shows overall market sentiment. For Biodesix, which operates in the defensive healthcare sector, overall optimism is important, but their growth depends more on the acceptance of their tests by insurance companies and doctors.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Biodesix Inc.
Biodesix is a diagnostic detective for lung cancer treatment. They offer a portfolio of tests (including liquid biopsy and proteomics) that help doctors make faster and more accurate treatment decisions. This graph is a summary indicator of their commercialization. It reflects the volume of their tests and their ability to convince doctors and (more importantly) insurers of the clinical value of their approach.
AKIMA Market Segment Index - Cancer analysis
Biodesix (BDSX) is a diagnostics company that uses AI and multi-omics (genomics, proteomics) to develop tests to help doctors treat lung diseases, primarily cancer. The chart shows the average index for the segment, helping investors assess how well Biodesix competes in the cancer testing sector compared to the industry average.
The AKIM Index for the overall market
Biodesix is a diagnostic company specializing in lung cancer. It offers blood tests for treatment decisions. This chart, reflecting the market average, is a backdrop. It helps assess how BDSX, a growth story in personalized medicine, compares to overall macroeconomic trends.
